WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Cassandra Rayer  1     Xavier Roblin  2     David Laharie  3     Mathurin Flamant  4     Marie Dewitte  1     Mathurin Fumery  5     Benedicte Caron  6     St├ęphanie Viennot  7     Benjamin Pariente     Laurent Siproudhis     Laurent Peyrin-Biroulet     Guillaume Bouguen    
1 CHU Pontchaillou,Rennes,France
2 University of St. Etienne Dept. de Gastroenterologie,Saint Etienne,France
3 CHU de Bordeaux Hopital Haut-Leveque,Pessac,France
4 Clinique Jules Verne,Nantes,France
5 Amiens University Hospital,Amiens,France
6 Hopital de Hautepierre,Strasbourg,France
7 CHRU de Caen HGE,Caen,F

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing